Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo˗Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Induction Therapy With 2 Doses of TD-1473 in Subjects With Moderately-to-Severely Active Crohn's Disease

Next Previous
Trial Profile

A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo˗Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Induction Therapy With 2 Doses of TD-1473 in Subjects With Moderately-to-Severely Active Crohn's Disease

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Izencitinib (Primary)
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Acronyms DIONE
  • Sponsors Theravance Biopharma

Most Recent Events

  • 15 Jun 2023 This trial has been completed in Bulgaria (End Date: 30 Mar 2023), according to European Clinical Trials Database record.
  • 14 Jan 2022 This trial has been discontinued in Germany (End Date: 31 Dec 2021), according to European Clinical Trials Database record.
  • 11 Jan 2022 Status changed from active, no longer recruiting to discontinued. The decision was made following the planned review of trial data by the independent datamonitoring committee who determined that, while there are no safety concerns, there are concerns about the ongoing benefit-risk of continuing the trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top